Michael Makris Shares 2 Fascinating Lessons from Hemophilia Care in Japan
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, UK. Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis, shared a post on LinkedIn:
”Two surprising facts I learnt about hemophilia care from my visit to Japan:
1. There are 7,000 patients with hemophilia A or B in Japan. They receive their care from 800 medical facilities. There are around 100 hemophilia treatment centres, but not all patients are seen here. Many patients have their hemophilia care provided by their local General Practitioners.
I find it difficult to understand how modern hemophilia care can be adequately provided outside hemophilia centres.
2. A number of consultant hematologists in Japan actually have hemophilia themselves. At dinner one evening I was sitting at a table with five consultant hematologists with hemophilia.”
During a recent visit to Japan, Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, UK. Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis, observed two surprising aspects of hemophilia care in the country.
Firstly, among Japan’s 7,000 patients with hemophilia A or B, care is delivered across 800 medical facilities, with only around 100 designated hemophilia treatment centers.
Remarkably, many patients are managed by local General Practitioners rather than specialized centers—a model that raises questions about maintaining comprehensive, modern standards of care.
Secondly, Professor Michael Makris encountered a uniquely personal dimension of the medical community: several consultant hematologists in Japan live with hemophilia themselves.
In one memorable instance, he shared a dinner table with five consultant hematologists who have hemophilia—a testament to resilience and dedication within the field.
These reflections highlight distinctive features of Japan’s approach to hemophilia care, prompting consideration of care models and patient-professional dynamics worldwide.
More interesting facts about hemophilia featured in Hemostasis Today.
-
Jul 20, 2025, 16:435 Reasons LD May Outperform EVD in aSAH: Is Lumbar Drainage the Superior Strategy?
-
Jul 18, 2025, 12:18NBCA Hosts PEP Talk with Dr. Parks on Aging and Blood Clots
-
Jul 18, 2025, 12:14WFH Shares Powerful Patient Story on Access to Bleeding Disorders Treatment
-
Jul 18, 2025, 11:53HTRS Shines Spotlight on Faculty Powering the Future of Hemostasis and Thrombosis
-
Jul 16, 2025, 17:23ISTH 2025 Spotlight: HOPE-B Trial Highlights Sustained Efficacy of Gene Therapy for Hemophilia B
-
Jul 20, 2025, 17:12Thromboelastography: Coagulation Beyond INR and aPTT
-
Jul 20, 2025, 16:555 Crucial Insights into Low VWF QL: Uncovering a Distinct Cause of Bleeding
-
Jul 19, 2025, 17:16Promising 85% Response: Ru-D Regimen Shows Hope for Adults with HLH
-
Jul 19, 2025, 16:16A Potential Link to Recurrent Pregnancy Loss: Monoclonal Anti-PF4 Antibodies' Role
-
Jul 19, 2025, 15:2115% Recanalization Rate During Transfer in Basilar Artery Occlusion: A Missed Opportunity?
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Jul 13, 2025, 15:35World’s First Liver Transplant for Plasminogen Deficiency Performed at KFSHRC
-
Jul 7, 2025, 17:08Detecting Anti-Drug Antibodies to Emicizumab: A French Center’s Remarkable Experience
-
Jul 20, 2025, 17:17Michael Makris Shares 2 Fascinating Lessons from Hemophilia Care in Japan
-
Jul 16, 2025, 10:24Salma Ismail: Honored to Be Invited By the EHA2025 as Part of Their Lighting the Flame Program
-
Jul 15, 2025, 17:002022 Chemistry Laureate Carolyn Bertozzi Shares Inspiring Advice for Young Scientists
-
Jul 15, 2025, 16:42A 200+ Year Historical Review of Women and Hemophilia: Shifting Perspectives
-
Jul 10, 2025, 18:25Dr. Carol Kasper: Honoring the Legacy